ロード中...
Economic Outcomes in Patients with Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate Plus Prednisone
INTRODUCTION: Prostate cancer (PC) is the second leading cause of cancer death among US men and accounts for considerable healthcare expenditures. We evaluated economic outcomes in men with chemotherapy-naïve metastatic castration-resistant PC (mCRPC) treated with enzalutamide or abiraterone acetate...
保存先:
| 出版年: | Adv Ther |
|---|---|
| 主要な著者: | , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Springer Healthcare
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7467473/ https://ncbi.nlm.nih.gov/pubmed/32112280 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12325-020-01260-x |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|